Study to Investigate the Efficacy of an Occluding Dentifrice in Providing Relief From Dentine Hypersensitivity

NCT02773758 | Completed Phase 4 Results

• 1 other identifier: 205201
• Study Type: interventional
• Target: 143
• Locations: 1 country
• Sites: 1

Brief Summary

This will be a single centre, two week, randomised, examiner blind, two treatment arm, parallel design, stratified (by maximum baseline Schiff sensitivity score of the two selected test teeth), controlled study, in participant with at least two sensitive teeth that meet the study criteria at the Screening and Baseline visits. The study will be conducted in participants in good general health, with pre-existing self-reported and clinically diagnosed tooth sensitivity at screening.

Conditions

Dentin Sensitivity

Outcome Measures

Primary Outcomes (1)

• Change From Baseline in Schiff Sensitivity Score at Day 14

  Schiff Sensitivity Score is an examiner based index, was scored immediately following administration of the evaporative air stimulus by directing a maximum one second application of air from a dental air syringe to the exposed dentine surface from a distance of approximately 1 cm. The examiner indicated the participant's response to the evaporative air stimulus, after the stimulation of each individual tooth, using the Schiff sensitivity scale as follows: 0= participant does not respond to air stimulation; 1= participant responds to air stimulus but does not request discontinuation of stimulus; 2= participant responds to air stimulus and requests discontinuation or moves from stimulus; 3= participant responds to stimulus, considers stimulus to be painful, and requests discontinuation of the stimulus.

  Baseline, Day 14

Secondary Outcomes (2)

• Change From Baseline in Schiff Sensitivity Score at Day 7

  Baseline, Day 7

• Change From Baseline in Tactile Threshold at Day 7 and Day 14

  Baseline, Day 7 and Day 14

Study Arms (2)

Stannous Fluoride Dentifrice

EXPERIMENTAL

Participants will be instructed to topically dose a dry toothbrush with a full strip of toothpaste, then brush each of the two selected sensitive test teeth first, followed by the whole mouth thoroughly for at least 1 minute twice daily (morning and evening). Participants will be permitted to rinse with tap water.

Other: Stannous Fluoride Dentifrice

Sodium monofluorophosphate Dentifrice

OTHER

Participants will be instructed to topically apply a full brush head of toothpaste to a dry toothbrush, then brush the whole mouth thoroughly for at least 1 minute. Participants will be permitted to rinse with tap water.

Other: Sodium monofluorophosphate Dentifrice

Interventions

Stannous Fluoride Dentifrice OTHER

Experimental dentifrice containing 0.454%w/w stannous fluoride (1100ppm fluoride)

Stannous Fluoride Dentifrice

Sodium monofluorophosphate Dentifrice OTHER

Dentifrice containing 0.76% w/w sodium monofluorophosphate (1000ppm fluoride)

Sodium monofluorophosphate Dentifrice

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Demonstrates understanding of the study procedures, restrictions and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form.
• Aged 18-65 years inclusive.
• Good general and mental health with:
• No clinically significant and relevant abnormalities of medical history or oral examination.
• Absence of any condition that would impact on the participant's safety or wellbeing or affect the individual's ability to understand and follow study procedures and requirements.
• Self-reported history of dentinal hypersensitivity (DH) lasting more than six months but not more than 10 years.
• Minimum of 20 natural teeth.
• Minimum of 2 accessible non-adjacent teeth (incisors, canines, pre-molars), preferably in different quadrants, that meet all of the following criteria at screening: Signs of facial/cervical gingival recession and/or signs of erosion or abrasion (EAR).
• Tooth with MGI score =0 adjacent to the test area (exposed dentine) only and a clinical mobility of ≤1.
• Tooth with signs of sensitivity measured by qualifying evaporative air assessment (yes\[Y\]/No\[N\] response).
• Minimum of two, non-adjacent accessible teeth (incisors, canines, pre-molars), that meet all of the following criteria at screening:
• Tooth with signs of sensitivity, measured by response to a qualifying tactile stimulus (Yeaple ≤ 20g) and evaporative air assessment (Schiff sensitivity score ≥ 2).

You may not qualify if:

• Women who are breast-feeding, known to be pregnant or who are intending to become pregnant over the duration of the study.
• Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.
• Previous participation in this study or participation in another clinical study (including cosmetic studies) or receipt of an investigational drug within 30 days of the screening visit.
• Recent history (within the last year) of alcohol or other substance abuse.
• Presence of chronic debilitating disease which, in the opinion of the investigator, could affect study outcomes or causing xerostomia.
• Dental prophylaxis within 4 weeks of Screening.
• Tongue or lip piercing or presence of dental implants.
• Gross periodontal disease, treatment of periodontal disease (including surgery) within 12 months of Screening, scaling or root planning within 3 months of Screening.
• Teeth bleaching within 8 weeks of Screening.
• Tooth with evidence of current or recent caries, or reported treatment of decay within 12 months of Screening.
• Tooth with exposed dentine but with deep, defective or facial restorations, teeth used as abutments for fixed or removable partial dentures, teeth with full crowns or veneers, orthodontic bands or cracked enamel. Sensitive teeth with contributing aetiologies other than erosion, abrasion or recession of exposed dentine.
• Sensitive tooth not expected to respond to treatment with an over-the-counter dentifrice.
• Use of an oral care product indicated for the relief of dentine hypersensitivity within 8 weeks of screening.
• Daily doses of medication/treatments which, in the opinion of the investigator, could interfere with the perception of pain.
• Examples of such medications include analgesics, anticonvulsants, antihistamines that cause marked or moderate sedation, sedatives, tranquilisers, anti-depressants, mood-altering and anti-inflammatory drugs.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (1)

GSK Investigational Site

Mississauga, Ontario, L4W 0C2, Canada

Location

MeSH Terms

Conditions

Dentin Sensitivity

Condition Hierarchy (Ancestors)

Tooth Diseases; Stomatognathic Diseases

Results Point of Contact

• Title: GSK Response Center
• Organization: GlaxoSmithKline

866-435-7343

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 12, 2016
• First Posted: May 16, 2016
• Study Start: January 1, 2016
• Primary Completion: March 11, 2016
• Study Completion: March 11, 2016
• Last Updated: September 29, 2017
• Results First Posted: December 12, 2016

Record last verified: 2017-08

Locations

CA (1)